AIM AIM ImmunoTech Inc.
-
AIM ImmunoTech Missed Consensus Estimates
Friday, August 7, 2026 · 12:00 AM ET
AIM ImmunoTech (AIM) reported a loss of $0.43 per share on revenue of $0.03 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.12 per share. The company missed consensus estimates by 258.33% while revenue grew 4.00% on a year-over-year basis.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.43)
Earnings Whisper®
—
Consensus Estimate
($0.12)
Earnings Surprise
Earnings Growth
Reported Revenue
$0.03M
Revenue Estimate
—
Revenue Surprise
Revenue Growth